AIDS-related Kaposi's sarcoma: epidemiological, diagnostic, treatment and control aspects in sub-Saharan Africa.
Until the 1980s, little attention had been accorded to endemic Kaposi's sarcoma (KS), a neoplasm noted in several parts of Southern Europe and the African continent but with relatively slow progression, except in children and young adults. Furthermore, therapeutic approaches based on surgery, radiation and topical treatment were of limited efficacy, mostly used to overcome the disabling and stigmatizing effects of the disease. With the emergence of the HIV/AIDS epidemic, and the profound impact of KS on AIDS-related mortality, the pathogenesis of KS has been better studied, and the realisation that a virus (KS-associated Herpesvirus or Human Herpesvirus 8, or KSHV/HHV-8), combined with immunosuppression and cytokine-induced growth, was responsible for the development of this disease has led to novel therapeutic approaches. These are unfortunately still highly toxic, require careful monitoring, and are expensive, thus limiting their use in most parts of Africa. However, the use of highly active antiretroviral therapy (HAART), which has led to a considerable decline in KS incidence in populations of industrialized countries, constitutes the best hope for the control of this stigmatizing and lethal disease in Africa. Trials comparing different regimens of antiretroviral drugs in combination with systemic chemotherapeutic agents are urgently needed.
Sissolak
Gerhard
G
Department of Internal Medicine, Tygerberg Academic Hospital, Tygerberg, South Africa. sissolak@telkomsa.net
Mayaud
Philippe
P
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology; D000328:Adult; D017954:Africa South of the Sahara / Q000453:epidemiology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D003906:Developing Countries / Q000706:statistics & numerical data; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology*; D006566:Herpesviridae Infections / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D019288:Herpesvirus 8, Human; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D014983:Xeroderma Pigmentosum / Q000453:epidemiology* / Q000209:etiology / Q000628:therapy
D000970:Antineoplastic Agents; D016898:Interferon-alpha